Literature DB >> 17942884

Trastuzumab--mechanism of action and use.

Michalis V Karamouzis, Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17942884     DOI： 10.1056/NEJMc072213

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Native MAG-1 antibody almost destroys human breast cancer xenografts.

Authors:  William G North; Roy H L Pang; Guohong Gao; Vincent A Memoli; Bernard F Cole
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

2.  V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.

Authors:  Karin von Schwarzenberg; Tamás Lajtos; Làszló Simon; Rolf Müller; György Vereb; Angelika M Vollmar
Journal:  Mol Oncol       Date:  2013-09-05       Impact factor: 6.603

3.  In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.

Authors:  Yasaman Ardeshirpour; Victor Chernomordik; Moinuddin Hassan; Rafal Zielinski; Jacek Capala; Amir Gandjbakhche
Journal:  Clin Cancer Res       Date:  2014-03-26       Impact factor: 12.531

4.  Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.

Authors:  Hui Li; Wenyan Fu; Xiang Gao; Qunfang Xu; Hua Wu; Wenlong Tan
Journal:  Tumour Biol       Date:  2013-12-29

5.  HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.

Authors:  Juan Ma; Huamin Han; Deruo Liu; Wei Li; Hongxiang Feng; Xin Xue; Xiaoran Wu; Ge Niu; Ge Zhang; Yunfeng Zhao; Changzhen Liu; Hua Tao; Bin Gao
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.

Authors:  Michalis V Karamouzis; Georgia Dalagiorgou; Urania Georgopoulou; Afroditi Nonni; Michalis Kontos; Athanasios G Papavassiliou
Journal:  Oncotarget       Date:  2016-02-02

7.  Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Authors:  Kristina M Ilieva; Judit Fazekas-Singer; Daniela Y Achkova; Tihomir S Dodev; Silvia Mele; Silvia Crescioli; Heather J Bax; Anthony Cheung; Panagiotis Karagiannis; Isabel Correa; Mariangela Figini; Rebecca Marlow; Debra H Josephs; Andrew J Beavil; John Maher; James F Spicer; Erika Jensen-Jarolim; Andrew N Tutt; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2017-09-11       Impact factor: 7.561

8.  Rethinking Causation in Cancer with Evolutionary Developmental Biology.

Authors:  Katherine E Liu
Journal:  Biol Theory       Date:  2018-07-27

9.  A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control.

Authors:  Zhichen Sun; Zhenhua Ren; Kaiting Yang; Zhida Liu; Shuaishuai Cao; Sisi Deng; Lily Xu; Yong Liang; Jingya Guo; Yingjie Bian; Hairong Xu; Jiyun Shi; Fan Wang; Yang-Xin Fu; Hua Peng
Journal:  Nat Commun       Date:  2019-08-28       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.